Web研究について. シェア. ツイート. 東病院腫瘍内科では、より良い新規治療を患者さんに提供すべく、臨床研究活動を積極的に行っています。. 乳腺、泌尿器、婦人科、肉腫、原発不明がんの各分野において、新薬の治験や医師主導臨床試験を数多く実施して ... Web21 giu 2006 · Background: Based on reports of the efficacy of docetaxel (T) in STS, we undertook a phase I/II trial to determine the response rate (RR), dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of addition of T to doxorubicin (A) and ifosfamide (I) in advanced STS.. Methods: Patients with advanced, recurrent, or metastatic STS, without …
Protocol for the 2ND-STEP study, Japan Clinical Oncology
http://jcog.jp/document/1806.pdf Web22 mag 2024 · Trabectedin and eribulin are two agents that have been recently approved for the treatment of specific soft tissue sarcoma subtypes. They have proved to be a much-needed line of additional treatment for patients with these rare tumors, but their activity remains admittedly modest in most cases. Further exploitation of these novel agents is … middletown dental care
Keio University, Tokyo and other places - ResearchGate
Web8 mar 2024 · The JCOG1802 study is a multicenter, selection design, randomized phase II trial comparing trabectedin (1.2 mg/m 2 intravenously, every 3 weeks), eribulin (1.4 mg/m 2 intravenously, days 1 and 8, every 3 weeks), and pazopanib (800 mg orally, every day) in patients with unresectable or metastatic STS refractory to doxorubicin-based first-line … WebProtocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib. BMC Cancer, Mar 2024 WebAbstract. The optimal treatment of giant cell tumors of the pelvis and sacrum is controversial. Our current patient series was combined with cases identified in a review of the literature published in the past 50 years, yielding a combined group of 239 lesions for study. Recurrence rates were 49% for patients who had radiation therapy alone, 47 ... middletown dental palmer ave middletown nj